Rajdeep Singh, MD
Neurology · Charlotte, NCNPI 1568628691
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Catalyst Pharmaceuticals, Inc. at 40.0% of the total. Reporting peaked in 2023 at $6,976 and has fallen 95.1% since, to $343 in 2025.
Across 49 payments — averaging $274.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Catalyst Pharmaceuticals, Inc.$5K
- Sunovion Pharmaceuticals Inc.$3K
- SK Life Science, Inc.$2K
- Neuropace, Inc.$1K
- Medtronic$952
- UCB, Inc.$750
- plus $459 from 6 others
Across 8 payments — averaging $2282.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$18K
What the payments were for
- Speaking & faculty fees$5,95044%
- Travel & lodging$3,41525%
- Food & beverage$4,04630%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Catalyst Pharmaceuticals, Inc. | 4 | $5,392 |
| Sunovion Pharmaceuticals Inc. | 3 | $3,040 |
| SK Life Science, Inc. | 15 | $1,674 |
| Neuropace, Inc. | 5 | $1,204 |
| Medtronic | 7 | $952 |
| UCB, Inc. | 9 | $750 |
| Idorsia Pharmaceuticals US Inc | 1 | $123 |
| Eisai Inc. | 1 | $120 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $110 |
| Zimmer Biomet | 1 | $57 |
| Neurelis, Inc. | 1 | $35 |
| Ceribell, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$5,512
- APTIOM$3,019
- RNS Neurostimulator Kit$1,147
- ACTIVA$775
- XCOPRI$356
- Cenobamate$125
- QUVIVIQ$123
- LUMRYZ$110
How this compares
$13,471 in reported general payments places this provider in the 80th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 110 | $248,293 |
| XcopriCenobamate | 131 | $171,689 |
| BriviactBrivaracetam | 84 | $137,776 |
| Lamictal XrLamotrigine | 23 | $98,322 |
| FycompaPerampanel | 50 | $66,211 |
| VimpatLacosamide | 42 | $48,542 |
| Trokendi XrTopiramate | 12 | $39,370 |
| Keppra XrLevetiracetam | 17 | $34,633 |
| Lacosamide | 222 | $31,011 |
| NayzilamMidazolam | 25 | $30,652 |
| LamictalLamotrigine | 14 | $16,332 |
| Nurtec OdtRimegepant Sulfate | 17 | $15,928 |
| Clobazam | 55 | $13,697 |
| Levetiracetam | 234 | $7,733 |
| Lamotrigine ErLamotrigine | 20 | $5,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Aptiom | $3,040 | $248,293110 claims |
| UCB, Inc.Briviact, Vimpat, Nayzilam | $750 | $216,970151 claims |
| SK Life Science, Inc.Xcopri | $1,674 | $171,689131 claims |
| Eisai Inc.Fycompa | $120 | $66,21150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 566 neurology providers in North Carolina.
Other neurology in Charlotte
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Megan DonnellyCharlotte$601K
- Sanjay IyerCharlotte$581K
- Urvi DesaiCharlotte$262K
- Danielle Englert DoggettCharlotte$215K
- Robert WigginsCharlotte$138K
- Ardith CourtneyCharlotte$120K
- Joseph ChipmanCharlotte$118K
- Kurt WashburnCharlotte$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.